Omeros Corporation (OMER) Trading Down 5.6%
Omeros Corporation (NASDAQ:OMER) shares traded down 5.6% during mid-day trading on Monday . The company traded as low as $20.37 and last traded at $20.80, with a volume of 1,223,133 shares trading hands. The stock had previously closed at $22.03.
A number of research analysts have recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $47.00 price objective on shares of Omeros Corporation in a research note on Friday. ValuEngine raised Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Maxim Group set a $24.00 price objective on Omeros Corporation and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Cantor Fitzgerald set a $15.00 price objective on Omeros Corporation and gave the company a “hold” rating in a research note on Tuesday, June 13th. Finally, WBB Securities reaffirmed a “strong-buy” rating and set a $75.00 price objective on shares of Omeros Corporation in a research note on Wednesday, June 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $32.80.
The firm has a 50 day moving average price of $21.55 and a 200-day moving average price of $16.82. The stock’s market capitalization is $931.90 million.
Omeros Corporation (NASDAQ:OMER) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.12. The company had revenue of $17.15 million during the quarter, compared to the consensus estimate of $14.63 million. Omeros Corporation’s revenue was up 71.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.32) earnings per share. Equities research analysts predict that Omeros Corporation will post ($1.32) EPS for the current year.
In other Omeros Corporation news, VP Michael A. Jacobsen sold 24,000 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $21.20, for a total value of $508,800.00. Following the transaction, the vice president now directly owns 2,650 shares in the company, valued at approximately $56,180. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Michael A. Jacobsen sold 12,000 shares of the company’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $24.95, for a total transaction of $299,400.00. Following the completion of the transaction, the vice president now owns 19,500 shares in the company, valued at $486,525. The disclosure for this sale can be found here. 13.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently modified their holdings of the company. National Asset Management Inc. bought a new position in shares of Omeros Corporation during the first quarter worth approximately $158,000. Legal & General Group Plc boosted its stake in shares of Omeros Corporation by 7.8% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 751 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Omeros Corporation during the first quarter valued at $292,000. Highbridge Capital Management LLC acquired a new stake in shares of Omeros Corporation during the first quarter valued at $330,000. Finally, American International Group Inc. boosted its stake in shares of Omeros Corporation by 15.2% in the first quarter. American International Group Inc. now owns 24,521 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 3,232 shares during the last quarter. Institutional investors and hedge funds own 43.94% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.